A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma – the STRONG study: study protocol for a randomised controlled trial

BACKGROUND: Neovascular glaucoma (NVG) is rare, comprising only 3.9% of all glaucoma cases. The most common cause of NVG is ischaemic central retinal vein occlusion (iCRVO). NVG frequently results in blindness and painful end-stage glaucomatous damage leading to the need for enucleation. Currently,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorenz, Katrin, Scheller, Yvonne, Bell, Katharina, Grus, Franz, Ponto, Katharina A., Bock, Felix, Cursiefen, Claus, Flach, Jens, Gehring, Marta, Peto, Tunde, Silva, Rufino, Tal, Yossi, Pfeiffer, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356411/
https://www.ncbi.nlm.nih.gov/pubmed/28302155
http://dx.doi.org/10.1186/s13063-017-1861-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356411/
https://www.ncbi.nlm.nih.gov/pubmed/28302155
http://dx.doi.org/10.1186/s13063-017-1861-3

Ejemplares similares